1. Scrip
  2. >>Leadership
  3. >>Interviews

Leo Pharma Picks Up Momentum As Growth Plan Progresses

 
• By Jessica Merrill

CEO Christophe Bourdon talked to Scrip about the company’s revitalization as revenue grew 10% in the third quarter.

(Shutterstock)
Key Takeaways

Leo Pharma CEO Christophe Bourdon talked to Scrip about the company’s progress in dermatology and plans for business development.

In the first nine months of 2024, Leo’s dermatology revenue increased 13% to DKK 7.58bn ($1.07bn).

Leo is leveraging its small size, focus and agility as advantages as a potential partner, Bourdon said.

Leo Pharma’s turnaround plan has taken root and the company is now in a growth phase on the back of launches like Adbry/Adtralza (tralokinumab) for atopic dermatitis and Anzupgo (delgocitinib)...

Scrip interviewed CEO Christophe Bourdon about the Danish dermatology specialist’s progress and the next phase of its growth plan, shortly after the company announced third quarter sales growth of 10%....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Interviews

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

More from Business

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

Pfizer Scoops 3SBio’s PD-1/VEGF Bispecific In ADC Combo Push

 
• By Dexter Jie Yan

Pfizer is doubling down on partnerships for combination therapies involving its antibody-drug conjugates through a new alliance with China's 3SBio’s for a bispecific antibody, potentially worth up to $6bn.

CRISPR Thinks Outside Gene-Editing Box With Sirius Deal

 
• By Alaric DeArment

The gene-editing company is making a deal with RNA interference-focused Sirius, but still focusing on cardiovascular disease, a major area of its pipeline.